fda warning letters compounded semaglutide tirzepatide september 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Are Compounded GLP-1s Going Away?

Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-800-727-6500

While this provides important baseline protection, it leaves gaps: entire drug classes that athletes could test positive for despite using "certified" products

Those who complained of gastrointestinal adverse effects were also more likely to discontinue use as well as those who lost more weight

Semaglutide averages 15% of body weight

The need for ongoing monitoring and the risk of serious adverse events can make these medications a less appealing option for the long-term management of diabetes and obesity-related heart issues